Judy Joice - Durect SVP

DRRX Stock  USD 1.01  0.15  17.44%   

SVP

Ms. Judy R. Joice is Senior Vice President Operations and Corporationrationrate Quality Assurance of DURECT CORPORATION. Previously, Ms. Joice served as our Vice President, Corporationrationrate Quality Assurance since July 2008 and as our Executive Director, Quality Assurance from July 2007 to July 2008. She has over 25 years experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread, Roche Pharmaceuticals, and Syntex Research. During her career, Ms. Joice has gained broad experience in CMC development activities including novel excipients, new chemical entities, devices, and combination products. She has developed, implemented and managed all aspects of companywide quality systems and compliance functions, ranging from drug development through commercial manufacturing since 2014.
Age 67
Tenure 10 years
Address 10240 Bubb Road, Cupertino, CA, United States, 95014-4166
Phone408 777 1417
Webhttps://www.durect.com
Joice has a B.S. in Chemistry from California State University, Hayward.

Durect Management Efficiency

The company has return on total asset (ROA) of (0.397) % which means that it has lost $0.397 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9988) %, meaning that it created substantial loss on money invested by shareholders. Durect's management efficiency ratios could be used to measure how well Durect manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.74 in 2024. Return On Capital Employed is likely to rise to -1.93 in 2024. At this time, Durect's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.2 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 121.6 K in 2024.
Durect currently holds 20.75 M in liabilities with Debt to Equity (D/E) ratio of 0.68, which is about average as compared to similar companies. Durect has a current ratio of 4.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Durect's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 2 records

SVP Age

Thomas McCourtIronwood Pharmaceuticals
67
Adi FrishRedhill Biopharma
54
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Durect Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. Durect (DRRX) is traded on NASDAQ Exchange in USA. It is located in 10240 Bubb Road, Cupertino, CA, United States, 95014-4166 and employs 48 people. Durect is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Durect Leadership Team

Elected by the shareholders, the Durect's board of directors comprises two types of representatives: Durect inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Durect. The board's role is to monitor Durect's management team and ensure that shareholders' interests are well served. Durect's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Durect's outside directors are responsible for providing unbiased perspectives on the board's policies.
James DVM, CEO, CoFounder
Jian MBA, Corporate Finance
Su Yum, Executive Officer
Norman MD, Chief Officer
Keith MBA, Commercial Development
Timothy MBA, CFO Secretary
Andrew Miksztal, VP Scientist
WeiQi MD, Executive Scientist
Judy Joice, Sr. VP of Operations and Corporate Quality Assurance
Steve JD, VP Counsel

Durect Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Durect a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Durect Stock Analysis

When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.